Assessing the Burden of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Background and Significance:
In the United States approximately 220,000 patients undergo cardiac surgery per annum. Among potential complications, the incidence of atrial fibrillation (AF) is estimated at 30 - 60 %, and therefore presents the most common adverse event after cardiac surgery. Multiple complications may be associated with AF: Patients are usually subject to an increased length-of-stay in the intensive care unit and in the hospital. Furthermore, the risk for stroke and development of long-term AF is elevated, while further anticoagulation is required putting the patient at risk for bleeding. On average, an additional $10,000 - $20,000 is spent for each patient with AF. However, the exact burden of postoperative AF still remains unknown.
Specific Aims of Research Project:
- To collect data from an electrocardiogram (EKG) monitoring patch, we aim to accurately determine the prevalence of atrial fibrillation in patients undergoing cardiac surgery at our center.
- To collect data on epidemiological characteristics to investigate risk factors for developing perioperative atrial fibrillation in patients undergoing cardiac surgery. This will allow us to create robust risk prediction models.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jakob Wollborn, MD MPH
- Phone Number: 6175258156
- Email: jwollborn@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Jochen D Muehlschlegel, MD, MMSc
- Phone Number: 617-732-7330
- Email: jmuehlschlegel@bwh.harvard.edu
-
Sub-Investigator:
- Jochen D Muehlschlegel, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Elective open heart surgery
- Age > 20 years
Exclusion Criteria:
- Refusal to participate (patient or health care proxy)
- Participation in other pharmacological trials
- Lack of data or poor data quality which cannot be analyzed for any heart rhythm in 80% of the postoperative study period.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing cardiac surgery
|
Collection of EKG data
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Atrial Fibrillation
Time Frame: Up to 30 days after discharge from the hospital
|
Atrial Fibrillation
|
Up to 30 days after discharge from the hospital
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Other arrhythmias
Time Frame: Up to 30 days after discharge from the hospital
|
Other arrhythmias
|
Up to 30 days after discharge from the hospital
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021P000356
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
NCT07298473RecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)
-
NCT07601763RecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field Ablation
-
NCT06260670CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial Fibrillation
-
NCT07187115RecruitingAtrial Fibrillation (AF) | Persistant Atrial Fibrillation
-
NCT05883631Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or Persistent
-
NCT03732794Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial Fibrillation
-
NCT07444320RecruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
NCT03075930UnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene Variants
-
NCT07633509Not yet recruitingAtrial Fibrillation (AF) | Atrial Fibrillation Catheter Ablation
-
NCT07575828Not yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
Clinical Trials on Vivalink wearable life sensors
-
NCT05655832Completed
-
NCT04322084Withdrawn
-
NCT03431025UnknownStroke | Hemiparesis
-
NCT06644859Active, not recruitingWomen | Age ≥45 | After Menopause or Without Intention of Pregnancy
-
NCT04756869Completed